Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
Paul G. Richardson(Harvard University), Meletios Α. Dimopoulos(Korea University), Jan Dürig(Essen University Hospital), Paweł Robak(Medical University of Lodz), Darrell White(Dalhousie University), Katja Weisel(Universität Hamburg), Alessandra Larocca(Cornell University), Morten Salomo(Copenhagen University Hospital), Meral Beksaç(Ankara University), Münci Yağcı(Gazi University), Larry D. Anderson(Dana-Farber Cancer Institute), Lara Grote(Bristol-Myers Squibb (United States)), Filiz Vural(Ege University), Albert Oriol(Institut Català d'Oncologia), Monika Engelhardt(University Medical Center Freiburg), Abraham S. Kanate(HonorHealth), Anna Marina Liberati(University of Perugia), Jindriska Lindsay(East Kent Hospitals University NHS Foundation Trust), Fredrik Schjesvold(Oslo University Hospital), Mónica Galli(Ospedale Papa Giovanni XXIII), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Michel Pavic(University of Bologna), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Ruiyun Jiang(Bristol-Myers Squibb (United States)), Philippe Moreau(Centre National de la Recherche Scientifique), Teresa Peluso(Bristol-Myers Squibb (Switzerland)), Alessandro Corso(Aziende Socio Sanitarie Territoriale Ovest Milanese), Pieter Sonneveld(Erasmus MC Cancer Institute)
Cited by 11
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k